Neuronetics Osake

Neuronetics Bruttokate

Bruttokate yhtiöstä Neuronetics (STIM) 16.8.2026 päivämäärällä on 48,48 %. Edellisenä vuonna Bruttokate oli 72,32 % — muutos −32,97 % (matalampi).

Bruttokate

48,48 %

YoY

−32,97%

Viimeksi päivitetty:

Bruttokate yhtiöstä Neuronetics on 2026 48,48 % . Bruttokate yhtiöstä Neuronetics oli 2025 72,32 % . Se laskee −32,97% matalampi edelliseen vuoteen verrattuna.

For Neuronetics, the gross margin of 48,5% is down versus 78,9% a few years ago.

Access this data via the Eulerpool API

Neuronetics Osakeanalyysi

Mitä Neuronetics tekee? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Neuronetics osakkeesta

Yhtiön Neuronetics Bruttokate on 48,48 % vuonna 2026.

Bruttokate yhtiöstä Neuronetics muuttui arvosta 72,32 % arvoon 48,48 %, mikä edustaa −32,97 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää Bruttokate Neuronetics:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Bruttokate mittaa prosenttiosuuden liikevaihdosta, joka jää jäljelle valmistuskustannusten jälkeen. Korkeammat bruttokatteet viittaavat tehokkaampaan tuotantoon ja vahvempaan hinnoitteluvoimaan.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata Bruttokate:n Neuronetics alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Arvioidakseen Bruttokate:n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja Bruttokate:lle.

Access this data via the Eulerpool API

Katteprosentit — Neuronetics

Kaikki tunnusluvut — Neuronetics